Claritev AI Stock Analysis
Want to see CTEV full AI Analyst Report?
Claritev (CTEV) AI Stock Analysis
Claritev
(NYSE:CTEV)
The score is held back primarily by elevated financial risk (heavy leverage/negative equity and ongoing net losses). Offsetting this, the latest earnings call was strongly positive with raised guidance and improving cash-flow expectations, while technicals are moderately supportive but not strongly bullish and valuation remains constrained by losses (negative P/E and no dividend yield provided).
Claritev (CTEV) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $478.09M
- Dividend Yield
- ―
- Average Volume (3M)
- 202.09K
- Price to Earnings (P/E)
- -1.7
- Beta (1Y)
- 2.85
- Revenue Growth
- 6.94%
- EPS Growth
- 21.64%
- Country
- US
- Employees
- 3,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Claritev Business Overview & Revenue Model
Company Description
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States....
Claritev Earnings Call Summary
The call was strongly positive. Management reported revenue, adjusted EBITDA, bookings, pipeline, client additions, claims activity, and cash-flow expectations that exceeded or improved against prior expectations. The company also raised full-year guidance, projected at least $1.1 billion of revenue in 2027, and highlighted diversification, AI deployment, and product innovation. Offsetting concerns included lower adjusted EBITDA margin, declines in Network and Payment & Revenue Integrity revenue, third-quarter free cash flow usage, 7.7x net leverage, and continued uncertainty around NSA rule changes, but the positive developments significantly outweighed the challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Claritev raised full year revenue guidance to $1.038 billion to $1.043 billion, implying full year revenue growth of 7.5% to 8% and Q4 revenues of $270 million at the midpoint, a low single-digit sequential increase and 9.5% growth over Q4 '25; adjusted EBITDA guidance is $625 million to $630 million, free cash flow guidance is $10 million to $20 million, and capital expenditure guidance is $165 million to $170 million. Q4 operating cash flow is expected to be $110 million to $120 million, with growth of 66% to 81% year-over-year, and free cash flow is expected to be $74 million to $84 million, with growth of 103% to 131%; full year '26 cash conversion is expected to be greater than 50%. ACV bookings are expected to be $115 million to $125 million for the full year, representing 70% to 90% growth over '25. For '27, Claritev expects to achieve at least $1.1 billion of revenue, expects Payment & Revenue Integrity to return to growth, expects Network to be up about 5% excluding the onetime revenue this year, and plans to provide more comprehensive adjusted EBITDA and free cash flow guidance in February while maintaining a high [ SAU ] ratio.
Claritev Financial Statement Overview
Summary
Revenue is improving and operating metrics are stabilizing (positive EBIT and positive operating cash flow), but the company remains deeply unprofitable at the net level and the balance sheet is highly stressed (very high debt and negative equity), which materially increases financial risk.
Income Statement
34NegativeBalance Sheet
18Very NegativeCash Flow
46Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.02B | 965.41M | 930.62M | 961.52M | 1.08B | 1.12B |
| Gross Profit | 343.50M | 266.58M | 691.22M | 726.06M | 875.62M | 942.31M |
| EBITDA | 488.63M | 475.44M | -1.01B | 651.93M | 158.32M | 814.99M |
| Net Income | -275.14M | -284.28M | -1.65B | -91.70M | -572.91M | 102.08M |
Balance Sheet | ||||||
| Total Assets | 4.68B | 4.89B | 5.15B | 6.96B | 7.37B | 8.22B |
| Cash, Cash Equivalents and Short-Term Investments | 10.14M | 16.81M | 16.85M | 71.55M | 334.05M | 185.33M |
| Total Debt | 4.63B | 4.63B | 4.54B | 4.57B | 4.78B | 4.93B |
| Total Liabilities | 5.02B | 5.06B | 5.07B | 5.26B | 5.58B | 5.88B |
| Stockholders Equity | -346.60M | -173.90M | 84.02M | 1.71B | 1.79B | 2.34B |
Cash Flow | ||||||
| Free Cash Flow | -27.82M | -12.28M | -10.51M | 62.87M | 282.63M | 320.10M |
| Operating Cash Flow | 131.31M | 117.32M | 107.62M | 171.72M | 372.36M | 404.69M |
| Investing Cash Flow | -163.43M | -121.02M | -118.12M | -249.79M | -104.45M | -228.38M |
| Financing Cash Flow | 4.51M | 2.36M | -41.31M | -180.99M | -115.74M | -114.68M |
Claritev Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Positive. The current price of 28.21 is above the 20-day moving average (MA) of 23.25, above the 50-day MA of 26.70, and above the 200-day MA of 25.45, indicating a bullish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 61.86 is Neutral, neither overbought nor oversold. The STOCH value of 76.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTEV.
Claritev Risk Analysis
Claritev disclosed 62 risk factors in its most recent earnings report. Claritev reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksClaritev Peers Comparison
Overall Rating
WAY76Outperform
CCLD73Outperform
PHR69Neutral
EVH58Neutral- CTEV52Neutral
HCAT51Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| WAY | 76Outperform | $5.64B | 41.20 | 3.41% | ― | 21.43% | 9.80% |
| CCLD | 73Outperform | $111.90M | 20.42 | 24.48% | ― | 14.86% | 214.99% |
| PHR | 69Neutral | $814.99M | 74.39 | 3.01% | ― | 12.93% | ― |
| EVH | 58Neutral | $542.91M | -1.12 | -129.54% | ― | 14.06% | -189.46% |
| CTEV | 52Neutral | $489.53M | -1.72 | 104.20% | ― | 6.94% | 21.64% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HCAT | 51Neutral | $109.66M | -0.51 | -128.24% | ― | -13.88% | -78.38% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CTEV | Claritev Corporation | 28.21 | -15.99 | -36.18% | |
| CCLD | Carecloud, Inc. | 2.65 | -0.53 | -16.67% | |
| EVH | Evolent Health Inc. | 4.99 | 0.83 | 19.95% | |
| PHR | Phreesia | 12.81 | -9.72 | -43.14% | |
| HCAT | Health Catalyst | 1.43 | -0.92 | -39.15% | |
| WAY | Waystar Holding Corp. | 28.84 | -6.91 | -19.33% |
Claritev Corporate Events
Claritev adds Jenni Main to board and audit committee
PositiveOn October 15, 2026, Claritev expanded its Board of Directors from eleven to twelve members and appointed Jennifer (Jenni) Main as a Class II director and member of the Audit Committee, replacing Jason Kap on that committee. Main will receive standar...
Claritev Adds AI Expert Ben Letham to Board
PositiveOn September 14, 2026, Claritev Corporation appointed AI expert Ben Letham to its Board of Directors as a Class I director and member of the Risk Committee, filling the vacancy created by the passing of director John Prince. Letham will serve as a no...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026